Program Offering and Eligibility
With the Evrysdi Co-pay Program, eligible, commercially insured patients pay as little as $5 per 30-day supply of Evrysdi. The program covers the rest of the patient's co-pay or co-insurance, up to $25,000 in assistance per 12-month period.
There are no income requirements for the Evrysdi Co-pay Program.
TO BE ELIGIBLE FOR THE Evrysdi CO-PAY PROGRAM, PATIENTS MUST:
- Be taking Evrysdi for an FDA-approved indication
- Have commercial (private or non-governmental) insurance. This includes plans available through state and federal health insurance marketplaces
- Be 18 years of age or older or have a legal guardian 18 years of age or older to manage the program
- Not be a government beneficiary and/or participant in a federal or state-funded health insurance program (eg, Medicare, Medicare Advantage, Medigap, Medicaid, VA, DoD, TRICARE)
- Not be receiving assistance from the Genentech Patient Foundation or other charitable organizations for Evrysdi
- Not live in a state where co-pay programs are prohibited
If a patient is not eligible for the Evrysdi Co-pay Program, there may be other options for financial assistance. Call (833) EVRYSDI (833-387-9734) or visit Genentech-Access.com/Evrysdi to learn more.
Evrysdi is indicated for the treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.
Important Safety Information
Interactions with Substrates of MATE Transporters
- Based on in vitro data, Evrysdi may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K, such as metformin
- Avoid coadministration of Evrysdi with MATE (multidrug and toxin extrusion) substrates. If coadministration cannot be avoided, monitor for drug-related toxicities and consider dosage reduction of the coadministered drug if needed
- Evrysdi may cause embryofetal harm when administered to a pregnant woman. In animal studies, administration of Evrysdi during pregnancy or throughout pregnancy and lactation resulted in adverse effects on development
- Based on animal data, advise pregnant women of the potential risk to the fetus. Pregnancy testing is recommended for females of reproductive potential prior to initiating Evrysdi. Advise female patients of reproductive potential to use effective contraception during treatment with Evrysdi and for at least 1 month after the last dose
- There is no data on the presence of Evrysdi in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Evrysdi and any potential adverse effects on the breastfed infant
Potential Effects on Male Fertility
- Male fertility may be compromised by treatment with Evrysdi. Counsel male patients on the potential effects on fertility. Male patients may consider sperm preservation prior to treatment
Most Common Adverse Reactions
- The most common adverse reactions in later-onset SMA (incidence in at least 10% of patients treated with Evrysdi and more frequent than control) were fever, diarrhea, and rash
- The most common adverse reactions in infantile-onset SMA were similar to those observed in later-onset SMA patients. Additionally, adverse reactions with an incidence of at least 10% were upper respiratory tract infection, pneumonia, constipation, and vomiting
You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Please see accompanying full Prescribing Information for additional Important Safety Information.